Hero banner

Pulmonary Embolism

Pulmonary Embolism Resource Hub

Venous thromboembolism is a serious disease. Both deep vein thrombosis and pulmonary embolism frequently result in devastating impacts for patients in both the short and the long term. Pulmonary Embolism affects about 1000 out of every 1 million people with 200 of those cases considered to have an intermediate-high and high risk of mortality. Pulmonary Embolism, while preventable, is the 3rd leading cause of cardiovascular death.
 

As high mortality rates have shown little improvement over the last 20 years, it is clear acute PE patients need to be managed differently. We know that conservative treatment options, as recommended by the guidelines, leave thrombus behind in 20-50% of patients. Literature shows the mortality number on anticoagulation only is still high and the majority of venous clot is lytic-resistant by the time of treatment. Thrombolysis comes with significant risk of bleeds. 

This section presents key papers, IHR and HR PE case reports, and also interviews with Key Opinion Leaders discussing how new technologies, like a lytic-free thrombectomy, can transform the treatment of acute Pulmonary Embolism.

Endorsed by Prof Felix Mahfoud
Pulmonary embolism remains a leading cause of cardiovascular death, with high mortality and morbidity rates showing little improvement over the last 20 years. This section explores how innovative treatment options, such as mechanical thrombectomy, along with new approaches to risk stratification and patient selection, can improve acute PE management and patient outcomes.

As high mortality rates have shown little improvement over the last 20 years, it is clear acute PE patients need to be managed differently. We know that conservative treatment options, as recommended by the guidelines, leave thrombus behind in 20-50% of patients. Literature shows the mortality number on anticoagulation only is still high and the majority of venous clot is lytic-resistant by the time of treatment. Thrombolysis comes with significant risk of bleeds. 

This section presents key papers, IHR and HR PE case reports, and also interviews with Key Opinion Leaders discussing how new technologies, like a lytic-free thrombectomy, can transform the treatment of acute Pulmonary Embolism.

Endorsed by Prof Felix Mahfoud
Pulmonary embolism remains a leading cause of cardiovascular death, with high mortality and morbidity rates showing little improvement over the last 20 years. This section explores how innovative treatment options, such as mechanical thrombectomy, along with new approaches to risk stratification and patient selection, can improve acute PE management and patient outcomes.

The Pulmonary Embolism Hub is supported by

Inari

Highlights

Dr Stotetsky on PEERLESS

Dr Stefan Stortecky (Bern University Hospital, Bern, CH) joins us to discuss outcomes from a parallel, non-randomised registry from the PEERLESS (NCT05111613) cohort. The contraindication cohort investigated large-bore mechanical thrombectomy with the FlowTriever system for intermediate-risk PE in patients with contraindications to thrombolytic therapy. 


 

Disrupting the Status Quo in PE Care

In this session, Prof Ingo Ahrens discusses the unmet needs in PE care and current risk stratifications, focusing on the gaps for intermediate-high risk patients and the need for structured assessment and rigorous scientific assessment of new reperfusion therapies.

Informed Decisions: Expanding Options for PE Patients

This session explores the current challenges faced in the ICU, and how new therapies could overcome these. Prof Thomas Cuisset discusses the current guidelines and consensus statements, and utilises a patient case study to illustrate and discuss the need for teamwork, robust clinical evidence and optimised risk stratification in PE care.

Review of the PE Clinical Trial Landscape

The key points of this session by Dr Stefan Stortecky include the history and timeline of randomised evidence in the PE clinical trial landscape, examining the rational and need for these studies, before discussing primary outcomes from PEERLESS, the first randomised clinical trial evaluating mechanical thrombectomy vs catheter directed thrombolysis.